New Drug Promises Dramatic Cardiovascular Hope
Swiss pharmaceutical giant Novartis’ new heart failure treatment has shown “remarkably positive” results in a global clinical trial of 8,400 patients. Participants in the trial of new drug LCZ696 cut their risk of dying or being hospitalized for heart-related ailments by 20 percent. The drug could be available as early as next year, but it won’t come cheap. While current generic heart drugs run $4 a month, LCZ696 is expected to cost a heart-stopping $200.